Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Marta Ebbing
WENBIT is one of the larger B-vitamin secondary prevention trials conducted in a population without mandatory folic acid fortification of foods. From 1999 to 2004, a total of 3090 patients (20.5% women) median (range) age 62 (28 – 87) years, undergoing coronary angiography for stable angina pectoris (84%), ACS (15%) or aortic valve stenosis (1%) at Bergen or Stavanger University, Western Norway, were included. Using two-by-two factorial design, participants were assigned to four groups receiving daily oral treatment with A) folic acid (0.8 mg)/vitamin B12 (0.4 mg)/vitamin B6 (40 mg), B) folic acid/vitamin B12, C) vitamin B6 alone or D) placebo. There were no significant differences in baseline characteristics between the four groups. Almost 60% of participants had 2- or 3-vessel disease. Homocysteine levels were lowered by 28% in groups receiving folic acid/vitamin B12, thus compliance was good. During a median follow-up of 38 months, 422 (13.7%) of patients experienced an event of the composite primary end point (all cause death, AMI, unstable angina pectoris or thromboembolic stroke). There were no significant differences in outcome when comparing groups receiving homocysteine-lowering folic acid or not, or comparing groups receiving vitamin B6 or not. In conclusion, WENBIT confirms and add additional evidence to the findings of earlier similar trials that have been completed the last few years.
At this time, B-vitamin supplementation is not justified as secondary prevention for coronary artery disease. To further assess possible effects of B-vitamin supplementation, meta-analyses of completed and ongoing trials should be conducted.
© 2016 European Society of Cardiology. All rights reserved